Zydus Lifesciences Limited (ZYDUSLIFE) AI Stock Analysis

• Market Cap: ₹896.15B
• Dividend Yield: 1.19%
• Average Volume (3M): 33.86K
• Price to Earnings (P/E): 22.1
• Beta (1Y): 0.56
• Revenue Growth: 14.01%
• EPS Growth: 14.62%
• Country: IN
• Employees: 26,921
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 10.26
• Shares Outstanding: 1,006,234,000
• 10 Day Avg. Volume: 33,597
• 30 Day Avg. Volume: 33,862
• PEG Ratio: 1.05
• Price to Book (P/B): 3.69
• Price to Sales (P/S): 3.80
• P/FCF Ratio: 17.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,015.00
• Price Target Upside: 10.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 45.39
• Revenue Forecast (FY): ₹264.12B

• Rating: 72 Outperform
• Price Target: ₹955.00 ▲(3.60% Upside)
• Action: Reiterated Date: 10/31/25
• Date: Action: Reiterated 10/31/25

Zydus Lifesciences' strong financial performance is the most significant factor, supported by robust revenue and profit growth, a healthy balance sheet, and strong cash flow generation. Technical analysis presents mixed signals, with bearish momentum offset by neutral RSI and moving averages. Valuation is fair, with a moderate P/E ratio and dividend yield. The absence of earnings call and corporate events data did not impact the score.

Positive Factors

Diversified revenue streams

Zydus generates revenue across finished formulations, international generics, APIs, consumer healthcare, CDMO and licensing. This diversification reduces reliance on any single market or product, smoothing cash flows and supporting resilience across regulatory and demand cycles over months.

High margins and sustained revenue growth

Elevated gross and operating margins alongside near-19% revenue growth indicate durable operational efficiency and pricing power across businesses. Sustained margins and top-line expansion support internal reinvestment and long-term profit retention rather than short-term episodic gains.

Strong cash generation

Very strong free cash flow growth and operating cash conversion above net income show the business reliably converts earnings into cash. This underpins investment capacity, dividend or buyback optionality, and balance sheet flexibility over the medium term.

Negative Factors

High total liabilities risk

Although leverage metrics appear low, the stated high absolute total liabilities create contingent risk (operational, contingent liabilities, or working capital stress). Elevated liabilities can constrain flexibility during adverse cycles and lengthen recovery time after shocks.

EPS growth lagging revenue growth

Revenue is expanding faster than EPS, suggesting earnings per share aren’t scaling one-for-one with sales. Over months this could reflect dilution, non-operating items, or margin mix shifts that limit per-share earnings improvement despite robust top-line growth.

Exposure to competitive generic markets

International generics growth depends on approvals, launch timing and intense competition. These structural dynamics can compress pricing and margins for prolonged periods, making forecastable revenue gains contingent on regulatory wins and product differentiation.

Zydus Lifesciences Limited Business Overview & Revenue Model

Company Description

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

How the Company Makes Money

Zydus Lifesciences makes money primarily by selling pharmaceutical products and related healthcare offerings across domestic and international markets. Key revenue streams include: (1) Finished dosage formulations: Revenue is generated from the manufacture and sale of prescription medicines (branded generics and generics) in India and exports to regulated and emerging markets; earnings depend on product mix, pricing, volumes, tender/contract wins (where applicable), and market access. (2) U.S. and other international generics: The company earns from launching and selling generic medicines abroad; performance is influenced by product approvals, competitive intensity, and the timing of launches (including complex generics where available). (3) Active pharmaceutical ingredients (APIs) and intermediates: Zydus supplies APIs used in its own formulations and sold to external customers, generating B2B manufacturing revenue linked to demand from pharmaceutical manufacturers and contract supply relationships. (4) Consumer healthcare/OTC and wellness products: It generates revenue from non-prescription and consumer-oriented healthcare brands sold through retail and distribution channels, typically benefiting from brand-led demand and marketing reach. (5) Contract development and manufacturing/other services: Where applicable, Zydus can earn service and manufacturing income by producing for partners or providing development/manufacturing capabilities. (6) Licensing, collaborations, and other income: The company may earn milestone payments, royalties, or collaboration income when it out-licenses products/technology or partners for development and commercialization; specific partnership terms and amounts are not provided here and are therefore null.

Zydus Lifesciences Limited Financial Statement Overview

Summary

Zydus Lifesciences demonstrates strong financial performance with impressive revenue and profit growth, a healthy balance sheet with low leverage, and robust cash flow generation. The high total liabilities pose a potential risk, but overall financial health remains strong.

Income Statement

Zydus Lifesciences has shown strong growth in its revenue and profitability. The gross profit margin stands at 72.7%, indicating efficient cost management. Net profit margin improved to 19.5%, reflecting enhanced profitability. Revenue growth rate is impressive at 18.9%, showing positive growth momentum. EBIT and EBITDA margins are also robust at 56.9% and 29.7%, respectively, showcasing operational efficiency.

Balance Sheet

The balance sheet displays healthy financial stability, with a low debt-to-equity ratio of 0.13, suggesting low leverage. The return on equity is strong at 18.9%, indicating effective use of equity. The equity ratio is also substantial at 64.4%, demonstrating a strong equity base. However, the high level of total liabilities could pose potential risks.

Cash Flow

Cash flow analysis shows a strong position with a free cash flow growth rate of 118.1%, indicating significant improvement in cash generation. The operating cash flow to net income ratio is 1.50, suggesting robust cash flow generation relative to net earnings. The free cash flow to net income ratio is 1.12, further validating strong cash flow management.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	244.94B	232.41B	195.47B	172.37B	151.10B	144.03B
Gross Profit	161.97B	167.03B	131.54B	107.67B	94.24B	94.60B
EBITDA	73.82B	68.30B	52.57B	35.34B	31.70B	34.15B
Net Income	49.20B	45.26B	38.59B	19.60B	44.87B	21.34B
Balance Sheet
Total Assets	468.97B	372.02B	292.81B	257.56B	277.95B	238.85B
Cash, Cash Equivalents and Short-Term Investments	70.69B	78.08B	13.58B	11.92B	35.05B	11.27B
Total Debt	96.36B	32.13B	8.04B	11.95B	42.21B	46.08B
Total Liabilities	188.07B	108.43B	71.79B	60.68B	87.42B	89.55B
Stockholders Equity	253.02B	239.53B	198.29B	175.16B	170.00B	129.92B
Cash Flow
Free Cash Flow	785.00M	50.64B	23.21B	16.58B	9.02B	24.39B
Operating Cash Flow	9.46B	67.77B	32.28B	26.89B	21.04B	32.93B
Investing Cash Flow	-51.93B	-83.72B	-14.75B	11.71B	-10.00B	-7.22B
Financing Cash Flow	40.45B	20.14B	-17.79B	-44.00B	-8.68B	-25.49B

Zydus Lifesciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 921.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZYDUSLIFE, the sentiment is Negative. The current price of 921.8 is above the 20-day moving average (MA) of 905.08, above the 50-day MA of 899.16, and below the 200-day MA of 950.23, indicating a bearish trend. The MACD of -6.94 indicates Positive momentum. The RSI at 37.67 is Neutral, neither overbought nor oversold. The STOCH value of 27.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ZYDUSLIFE.

Zydus Lifesciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZYDUSLIFE	72 Outperform	₹896.15B	22.07	―	1.19%	14.01%	14.62%
LUPIN	72 Outperform	₹1.06T	20.49	―	0.57%	15.49%	64.37%
DRREDDY	70 Outperform	₹1.08T	21.88	―	0.63%	14.10%	9.72%
CIPLA	68 Neutral	₹1.01T	45.14	―	0.87%	6.93%	21.55%
TORNTPHARM	66 Neutral	₹1.44T	51.30	―	0.84%	9.11%	18.76%
MANKIND	59 Neutral	₹825.51B	55.46	―	0.04%	23.22%	-19.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Zydus Lifesciences Limited Corporate Events

Zydus launches reusable multi-dose Semaglutide pen for diabetes and obesity in India

Zydus Lifesciences has launched Semaglutide Injection in India under the brand names SEMAGLYN, MASHEMA and ALTERME following patent expiry, targeting Type 2 diabetes and obesity. Approved by the Drug Controller General of India, the therapy is positioned for a wide patient base amid rapidly rising incidence of both conditions across the country.

Differentiating itself from existing options, Zydus is offering the drug in a prefilled 15mg/3ml cartridge used with an innovative reusable multi-dose pen device to which it holds exclusive rights. The device allows clinicians and patients to adjust various dose strengths from a single pen, aiming to improve adherence and convenience while cutting overall treatment costs to around Rs. 2,200 per month.

The launch directly addresses India’s worsening metabolic health crisis, where tens of millions live with diabetes and obesity prevalence has nearly doubled among women and more than doubled among men. By coupling a GLP-1 therapy with a cost-efficient, patient-friendly delivery system manufactured at its Ahmedabad biotech facility, Zydus strengthens its position in the high-growth diabetes and obesity segment and could expand access to advanced treatments for a broad population.

Zydus Lifesciences Publishes Q3 and 9M FY26 Investor Presentation

Zydus Lifesciences Limited has released an investor presentation detailing its unaudited financial results for the quarter and nine months ended December 31, 2025. The disclosure, made under SEBI’s Listing Regulations and shared with both BSE and NSE, underscores the company’s ongoing commitment to transparent financial reporting and regular communication with market participants.

The earnings presentation for Q3 and the first nine months of FY26 will give investors and analysts deeper insight into Zydus Lifesciences’ recent financial performance and operational trends. By formally submitting these materials to the exchanges, the company supports informed decision-making among stakeholders and reinforces its adherence to regulatory compliance and best practices in corporate governance.

Zydus Lifesciences Posts Strong Q3 and 9M FY26 Growth With Higher Margins

Zydus Lifesciences Limited reported a strong operational performance for the third quarter of FY26, with revenue from operations rising 30% year-on-year to Rs. 68,645 million and EBITDA up 31%, delivering a margin of 26.5%. The company invested Rs. 6,074 million in R&D during the quarter, maintained robust profitability with adjusted net profit of Rs. 11,109 million, and continued organic capex of Rs. 4,637 million.

For the nine months ended December 31, 2025, revenue grew 17% to Rs. 195,614 million, while EBITDA increased 20% with an improved margin of 30.3%. Adjusted net profit rose 15% to Rs. 38,640 million, and the balance sheet remained conservative with a net debt-to-equity ratio of 0.11x and net debt-to-EBITDA of 0.36x, underscoring financial strength to support ongoing R&D and capacity expansion.

Zydus Unveils World’s First Nivolumab Biosimilar in India to Broaden Cancer Care Access

Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the cancer immunotherapy drug Nivolumab, in the Indian market, reinforcing its capabilities in advanced biologics and immuno-oncology. Offered in 100 mg and 40 mg dosages at roughly one-quarter the price of the reference drug, Tishtha is designed to significantly improve affordability and reduce the overall treatment burden for cancer patients, with the company estimating potential benefit for more than 500,000 patients. The two-strength portfolio aims to help oncologists optimise dosing and minimise drug wastage, while domestic development and manufacturing are intended to ensure consistent, long-term availability of checkpoint inhibitor therapy across multiple treatment cycles, enhancing access to modern cancer care in India and strengthening Zydus’s position in the oncology and biosimilars space.

Zydus Lifesciences Opens Special Six-Month Window for Re-Lodgement of Physical Share Transfers

Zydus Lifesciences Limited has announced, via newspaper publication, the opening of a special six-month window from July 7, 2025 to January 6, 2026 for re-lodgement of transfer requests for physical shares, in line with a Securities and Exchange Board of India (SEBI) circular issued on July 2, 2025. This facility applies to physical share transfer requests originally lodged before April 1, 2019 that were rejected and returned due to documentation or process deficiencies, allowing investors who missed the earlier March 31, 2021 deadline to resubmit with proper documents through the company or its registrar and share transfer agent, with transfers to be completed only in demat form and no requests accepted after January 6, 2026.